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Abstract
Background: Osteoarthritis is a common presentation in primary care, and non-selective non-steroidal anti-
inflammatory drugs (sometimes also referred to as traditional NSAIDs or tNSAIDs) and selective cyclo-oxygenase 2
inhibitors (COX-2 inhibitors) are commonly used to treat it. The UK’s National Institute for Health and Clinical
Excellence (NICE) recommends taking patient risk factors into account when selecting a tNSAID or a COX-2
inhibitor, but GPs have lacked practical guidance on assessing patient risk.
Methods: A multi-disciplinary group that included primary care professionals (PCPs) developed an evidence-based
consensus statement with an accompanying flowchart that aimed at providing concise and specific guidance on
NSAID use in osteoarthritis treatment. An open invitation to meet and discuss the issue was made to relevant
healthcare professionals in South Yorkshire. A round table meeting was held that used a modified nominal group
technique, aimed at generating opinions and ideas from all stakeholders in the consensus process. A draft
developed from this meeting went through successive revisions until a consensus was achieved.
Results: Four statements on the use of tNSAIDs and COX-2 inhibitors (and an attached category of evidence) were
agreed: 1) tNSAIDs are effective drugs in relieving pain and immobility associated with osteoarthritis. COX-2 inhibitors
are equally effective; 2) tNSAIDs and COX-2 inhibitors vary in their potential gastrointestinal, liver, and cardio-renal
toxicity. This risk varies between individual treatments within both groups and is increased with dose and duration of
treatment; 3) COX-2 inhibitors are associated with a significantly lower gastrointestinal toxicity compared to tNSAIDs.
Co-prescribing of aspirin reduces this advantage; 4) PPIs should always be considered with a tNSAID and with a COX-2
inhibitor in higher GI risk patients. An accompanying flowchart to guide management was also agreed.
Conclusions: Individual patient risk is an important factor in choice of treatment for patients with osteoarthritis
and the consensus statement developed offers practical guidance for GPs and others in primary care. Where there
are clinical uncertainties, guidance developed and agreed by local clinicians has a role to play in improving patient
management.
Background
Osteoarthritis is a common presentation in primary care,
responsible for an estimated 2.4% of all GP consultations
in the UK, and a major contributor to the annual 10.1
million consultations for musculoskeletal conditions
overall [1]. Those with osteoarthritis have an increased
risk of death from any cause, and particular for mortality
related to cardiovascular disease and dementia [2].
Traditional non-steroidal anti-inflammatory drugs
(tNSAIDs) are effective drugs in relieving pain and inflam-
mation associated with osteoarthritis and other musculos-
keletal conditions, and in promoting mobility and physical
activity. They are commonly prescribed in primary care.
Agents that selectively inhibit cyclo-oxygenase 2 (COX-2
inhibitors) are equally effective [3-6].
In its guidance on osteoarthritis the National Institute
for Health and Clinical Excellence (NICE) recommends
initial management with education, advice and informa-
tion, strength and aerobic exercise, and weight loss for
overweight and obese patients, followed by treatment
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any medium, provided the original work is properly cited.with paracetamol or topical NSAIDs if initial treatment is
not successful [7].
Where paracetamol or topical NSAIDs are ineffective
for pain relief, NICE suggests consideration of an oral
non-selective NSAID or a COX-2 inhibitor, prescribed
with a proton pump inhibitor (PPI). The NICE guidance
suggests taking individual patient risk factors including
age into account when selecting a tNSAID or COX-2
inhibitor, with assessment and ongoing monitoring of
risk factors.
While the effectiveness of both tNSAIDs and COX-2
inhibitors is similar, the potential adverse effects vary. In
particular COX 2 inhibitors are associated with a lower
risk of gastrointestinal adverse effects compared to
tNSAIDS, and there is some evidence that naproxen is
associated with a lower cardiovascular risk than other
tNSAIDs [6,8].
The NICE guidance is a useful basis for clinical prac-
tice, but in their communications with GPs, for example
in referral letters and at educational events, rheumatolo-
gists in South Yorkshire identified some uncertainty
about its detailed application in the wake of rapidly-evol-
ving new evidence on the risks and benefits of tNSAIDs
and COX-2 inhibitors. In particular GPs were unsure
about how to assess the risk status of patients who could
benefit from a tNSAID or COX-2 inhibitor, and so to
identify the most appropriate treatment. Following the
high-profile withdrawal of the COX-2 inhibitor rofecoxib
in 2004 in the wake of concerns about cardiovascular
safety [9], and the subsequent withdrawals of valdecoxib
(because of a high rate of serious skin adverse effects and
concerns about cardiovascular safety) [10] and lumira-
coxib (because of severe hepatic adverse events) [11]
some GPs believed that all COX-2 inhibitors had been
withdrawn.
To address these uncertainties and in the light of addi-
tional clinical evidence, we therefore developed an evi-
dence-based consensus statement, and an accompanying
management flowchart to provide more specific guidance
for GPs and others working with osteoarthritis patients
in primary care. The aim of the consensus process was to
develop a practical, evidence-based statement, in line
with existing NICE guidance that would help GPs to
identify the risk status of patients with osteoarthritis and,
where appropriate, to provide the most effective appro-
priate tNSAID or COX-2 treatment for them.
Methods
The lead physician for the consensus statement (AOA),
issued an open invitation by email to relevant local spe-
cialists and primary care physicians. In response to this
invitation a group comprising a rheumatologist, a con-
sultant cardiologist, a consultant gastroenterologist, a
hospital pharmacist and three primary care physicians
with an interest in pain and/or rheumatology attended a
round table chaired by the lead physician (a consultant
rheumatologist). The key requirement for the project
was that the major specialties related to this topic were
represented. The meeting used a modified nominal
group technique in order to generate opinions and ideas
from all the relevant stakeholders who had expertise in
primary care, rheumatology, cardiology, gastroenterol-
ogy, pharmacy and pain relief.
Nominal group technique is a decision making method
that typically involves an initial silent generation of ideas
by individuals, without discussion or consultation with
others, followed by an uncritical sharing of ideas, group
discussion and then a ranking or evaluation of ideas [12].
It is regarded as an effective method of dealing with a
relatively closed issue, as here.
After the meeting the lead physician developed a draft
consensus statement and algorithm that went through sev-
eral successive drafts until a consensus statement and
accompanying flowchart was agreed by at least 90% of the
participants. In practice disagreements were minor and
the consensus statement was agreed by all participants.
The consensus group rated its recommendations (A
strongest, D weakest) based on the quality of the support-
ing evidence (with the strongest being evidence from a
meta-analysis of randomised controlled trials, and the
weakest being expert opinion).
The consensus statement and the flowchart has been
circulated to GPs and used in training activities.
Results
The consensus statement emphasised that tNSAIDs and
COX-2 inhibitors are effective at treating symptoms of
pain and immobility associated with osteoarthritis, but
that they vary in their potential for adverse effects, particu-
larly GI, cardiovascular, hepatic and renal. This risk varies
between individual treatments and increases with dose
and duration of treatment [6].
Recommendations
Four statements were developed for application in pri-
mary care, three supported by category A evidence and
one by category C evidence (see Table 1).
We also developed a flow chart illustrating a clinical
pathway for patients with osteoarthritis, based on NICE
guidance, and the additional work of the South York-
shire Clinical Consensus group (see Figure 1).
Risk prediction
The flowchart recommends calculating cardiovascular
risk prediction according to the Joint British Societies
guidelines on the prevention of cardiovascular disease in
clinical practice (JBS 2), based on calculations derived
from the Framingham study [13], and familiar to GPs in
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ing [14]. They are based on an algorithm that uses a
patient’s age, systolic blood pressure, total cholesterol to
HDL cholesterol ratio, and smoking status to calculate a
10 year risk of cardiovascular disease.
The NHS Clinical Knowledge Service has identified
the following patient groups at increased risk for gastro-
intestinal adverse effects from oral non-selective
NSAIDs:
Older age: the risk doubles with every decade after
the age of 55
Male sex: the risk of an upper GI complication is
twice as high in men than women
History of GI disorder such as gastroduodenal ulcer,
GI bleeding
Use of medications such as aspirin, warfarin, oral
corticosteroids, selective serotonin reuptake inhibi-
tors, venlafaxine or duloxetine
Serious comorbidity such as cardiovascular disease,
hepatic or renal impairment, diabetes or
hypertension
Prolonged NSAID use
Use of maximum dose NSAID
Presence of Helicobacter pylori infection
Excessive alcohol use
Heavy smoking[15].
The consensus group recommended this guidance as a
means of identifying GI risk in patients with
osteoarthritis.
The groups identified by the Clinical Knowledge Ser-
vice are:
Naproxen 500 mg bd or low dose ibuprofen (< 1,200
mg/day) plus a proton pump inhibitor (PPI) are recom-
mended as first choice NSAIDs where patients are at low
GI risk and moderate CV risk [7,16,17]. Both ibuprofen
and naproxen may inhibit the antiplatelet action of aspirin
and so other agents may be preferred in patients already
receiving low-dose aspirin for cardiovascular prophylaxis
who are likely to be at higher CV risk [18].
Recent evidence on opioid analgesics
We identified concern about the potential risks of
tNSAIDs and COX-2 inhibitors that resulted in some
GPs substituting opioid analgesics for osteoarthritis, per-
haps unaware of the significant risks associated with
opioid use. In the light of new evidence, the consensus
statement is cautious on the use of opioid analgesics,
and recommends they be restricted to patients with ser-
ious or absolute contraindications to tNSAIDs and
COX-2 inhibitors [19-21].
Recent research has questioned whether the initial
acute efficacy of opioid analgesics is sustained when
used for long-term treatment over weeks and months.
In addition, since the publication of the NICE guidance
in 2008 concern has been expressed about their risk-
benefit ratio in long term treatment of chronic muscu-
loskeletal pain. A recent review of more than 36,000
prescriptions found an significantly increased cumulative
risk over 12 months of cardiovascular events (myocar-
dial infarction, stroke, hospitalisation for heart failure,
coronary vascularisation and out of hospital cardiac
death) for patients taking opioid analgesics compared to
non-selective NSAIDs (p < 0.001) and to COX-2 inhibi-
tors (p = 0.004) [21]. There was, similarly an increased
risk of fractures, admission to hospital for safety events,
and all-cause mortality for those taking opioids com-
pared to non-selective NSAIDs or COX-2 inhibitors.
There was an increased risk of upper or lower GI bleed-
ing for opioids compared to COX-2 inhibitors (p =
0.04). The number needed to harm reported in this
study was small for opioids, and clinically relevant.
Diclofenac
In a departure from the NICE guidance, which does not
differentiate explicitly between different tNSAIDs, the
consensus statement explicitly recommends against the
Table 1 Use of non-steroidal anti-inflammatory drugs
Statement Category of
evidence
NSAIDs are effective drugs in relieving pain and immobility associated with osteoarthritis. COX-2 selective agents are equally
effective.
A*
NSAIDs and COX-2 inhibitors vary in their potential gastrointestinal, liver and cardio-renal toxicity. This risk varies between
individual treatments within both groups and is increased with dose and duration of treatment
A*
COX-2 selective agents are associated with a significantly lower gastrointestinal toxicity (PUBs and dyspepsia) compared to
non-selective NSAIDs. Co-prescribing of aspirin reduces this advantage.
A*
PPI should always be considered with a non-selective NSAID and with a COX-2 agent in higher GI risk patients. C†
*A-Directly based on evidence from a meta-analysis of randomised controlled trials or from at least one randomised controlled trials
†C Directly based on evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case control studies or
extrapolated from meta-analysis of randomised controlled trials, or extrapolated from at least one randomised controlled trial.
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recommendation was based on the strength of emerging
evidence (largely published after the development of the
NICE guidance) suggesting a higher cardiovascular risk
such as stroke, cardiovascular death and myocardial
infarction with diclofenac than other tNSAIDs and
selective COX-2 inhibitors [8,22,23]. This emerging evi-
dence suggests that it is prudent to take a precautionary
Figure 1 Management of osteoarthritis flowchart.
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eral alternative treatments to diclofenac when appropri-
ate for new patients.
A retrospective population-based nested case-control
analysis of data from the clinical records of more than 7
million patients registered with 468 UK general practices
found a 55% increased risk of MI for those taking diclo-
fenac, compared to those taking no tNSAIDs or COX-2
inhibitors in the previous 3 years (p <0 . 0 5 )[ 2 2 ] .T h e
increased risk for ibuprofen was 24% and for the now
withdrawn selective COX-2 inhibitor rofecoxib was 32%
(both p < 0.05) [22]. For diclofenac the number needed
to harm over a year was 521 treated patients for every
additional myocardial infarction, compared to 1,005 for
ibuprofen and 695 for rofecoxib. An observational study
found a 5.54-fold increase in the risk of death and a
2.24-fold increase in the risk of admission to hospital
with myocardial infarction in heart failure patients tak-
ing > 100 mg a day of diclofenac [23]. In a recent study
of a population of patients who had already had a myo-
cardial infarction, diclofenac was identified as the
tNSAID with the highest risk of death or recurrent MI
(HR3.26; 95%CI2.57-3.86) - about twice the risk of treat-
ment with any tNSAID (HR1.45;95%CI1.29-1.62) [24].
Selective COX-2 inhibitors
COX-2 inhibitors were recommended for patients identi-
fied to be at risk from GI toxicity but not at significant
CV risk (< 20% 10-year risk of an event according to the
Joint British Societies risk score [14]). There is evidence
that both COX-2 inhibition and use of a non-selective
NSAID plus PPI can reduce the risk of upper GI adverse
events [25-27], and evidence from a large prospective
randomised controlled trial of high risk patients that
COX-2 inhibitors may prevent gastrointestinal adverse
effects to a greater extent than a combination of tNSAID
and PPI [28]. This RCT, of patients with osteoarthritis or
rheumatoid arthritis who had a previous gastroduodenal
ulcer and allocated to treatment with celecoxib or diclo-
fenac and omeprazole, found a significant difference
between the proportion of patients on celecoxib who
developed a clinically significant upper or lower GI event
(20/2238, 0.9%), and those who developed an event on
tNSAID plus PPI treatment (81/2246, 3.8%), p <0 . 0 0 0 1
[28].
Future research
One outcome of reviewing national guidelines in a local
context as we did is coming across gaps in recommen-
dations, often because of a lack of supporting clinical
evidence. A number of clinical uncertainties were identi-
fied in developing the consensus statement, where
future research may be warranted. These included:
○ The efficacy, safety and cost effectiveness of COX-
2 inhibitors with and without PPI treatment versus
naproxen or ibuprofen with and without PPI
treatment
○ The CV safety of COX-2 inhibitors versus
tNSAIDs, including use of the 20% risk over 10
years threshold for CV appropriate NSAID
prescribing.
○ The clinical effects of COX-1 inhibition and the
pathogenesis of small bowel damage.
The first of these questions is addressed by the Pro-
spective Randomized Evaluation of Celecoxib Integrated
Safety vs. Ibuprofen or Naproxen (PRECISION). It is a
large-scale trial expected to recruit 20,000 participants
that should provide useful information about cardiovas-
cular safety of non-selective NSAIDs and selective
COX-2 inhibitors [29]. Results are scheduled for publi-
cation in 2014 [30].
Discussion
We aimed to produce clear, simple short guidance that
was easy to use and developed in a way that meant that
local clinicians would have a sense of local ownership.
These characteristics have been identified by GPs as fac-
tors likely to make them refer to a guideline [31].
Clinical guidelines can help improve the quality of
care when there is a lack of clarity about appropriate
clinical practice and when scientific evidence can pro-
vide an answer [32]. The uncertainty about the use of
non-selective, traditional NSAIDs and COX-2 inhibitors
recognised by specialists in South Yorkshire makes the
development of these guidelines an appropriate response
to potential suboptimal management of patients with
osteoarthritis. The consensus statement and accompany-
ing flowchart make a number of practical and achievable
recommendations to improve clinical treatment in pri-
mary care.
When choosing to manage osteoarthritis with tNSAIDS
and COX-2 inhibitors, GPs should make an appropriate
assessment including ongoing monitoring of GI and CV
risk to maximise the benefits and minimise the risks of
treatment. This consensus statement identifies practical
ways for GPs to do that. Risk profile can be influenced by
a number of factors including dose, concurrent aspirin
u s ea n da g e[ 3 3 ] .T h el o w e s te f f e c t i v ed o s es h o u l db e
used for the shortest possible duration, as chronic treat-
ment is associated with increased risk [34].
The reasons for the successful development of this
local consensus statement include its restricted focus on
a particular area of clinical uncertainty, its involvement
of a wide range of stakeholders, and the delivery of a
concise and practical clinical pathway.
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National clinical guidelines are effective ways to bring
about improvements in the quality of care, but they do
not always provide the practical guidance that primary
care professionals require. Where there are uncertainties
in clinical practice that might affect the quality of
patient care, local guidance developed by local groups of
clinicians has a role to play in health improvement.
Ascertaining individual patient risk is important when
choosing treatment for patients with osteoarthritis, and
the South Yorkshire consensus statement provides prac-
tical guidance for GPs and others in primary care to
measure risk and guide therapeutic decisions.
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